Sexcord/ stromal ovarian tumors other imaging findings

Jump to: navigation, search

Sexcord/ stromal ovarian tumors Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sexcord/ Stromal Ovarian Tumors from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sexcord/ stromal ovarian tumors other imaging findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sexcord/ stromal ovarian tumors other imaging findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sexcord/ stromal ovarian tumors other imaging findings

CDC on Sexcord/ stromal ovarian tumors other imaging findings

Sexcord/ stromal ovarian tumors other imaging findings in the news

Blogs on Sexcord/ stromal ovarian tumors other imaging findings

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Sexcord/ stromal ovarian tumors other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Maneesha Nandimandalam, M.B.B.S.[2]

Overview

PET-CT may be helpful in the diagnosis of sexcord/ stromal ovarian tumors. On fluorodeoxyglucose-positron emission tomography/computed tomography malignant ovarian tumors generally have intense uptake, whereas tumors with a small solid content show decreased uptake.

Other Imaging Findings

PET-CT scan and macroscopic findings in a recurrent patient (case 11). (A) PET-CT scan before treatment; a black arrow points to the metastatic tumor in the left portion of the fourth lumbar vertebra. (B) PET-CT scan after treatment. (C) and (D) show the retroperitoneal tumor fused by several para-aortic lymph node,Qian Q, You Y, Yang J, et al. Management and prognosis of patients with ovarian sex cord tumor with annular tubules: a retrospective study. BMC Cancer. 2015;15:270. Published 2015 Apr 12. doi:10.1186/s12885-015-1277-y,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408581/

References

  1. Qian Q, You Y, Yang J, Cao D, Zhu Z, Wu M, Chen J, Lang J, Shen K (April 2015). "Management and prognosis of patients with ovarian sex cord tumor with annular tubules: a retrospective study". BMC Cancer. 15: 270. doi:10.1186/s12885-015-1277-y. PMID 25886261.
  2. Bristow RE, Simpkins F, Pannu HK, Fishman EK, Montz FJ (April 2002). "Positron emission tomography for detecting clinically occult surgically resectable metastatic ovarian cancer". Gynecol. Oncol. 85 (1): 196–200. doi:10.1006/gyno.2002.6611. PMID 11925145.
  3. Tomimatsu T, Fukuda Y, Mimura K, Yoshino K, Kato H, Tsuboyama T, Hori Y, Kimura T (December 2016). "Intense fluorodeoxyglucose uptake by a benign sclerosing stromal tumor of the ovary". Taiwan J Obstet Gynecol. 55 (6): 893–894. doi:10.1016/j.tjog.2016.03.005. PMID 28040143.
  4. Matsutani H, Nakai G, Yamada T, Yamamoto K, Ohmichi M, Narumi Y (December 2018). "Diversity of imaging features of ovarian sclerosing stromal tumors on MRI and PET-CT: a case report and literature review". J Ovarian Res. 11 (1): 101. doi:10.1186/s13048-018-0473-1. PMC 6302382. PMID 30572921.
  5. Kitajima K, Ueno Y, Maeda T, Murakami K, Kaji Y, Kita M, Suzuki K, Sugimura K (November 2011). "Spectrum of fluorodeoxyglucose-positron emission tomography/computed tomography and magnetic resonance imaging findings of ovarian tumors". Jpn J Radiol. 29 (9): 605–8. doi:10.1007/s11604-011-0610-x. PMID 21956364.

Linked-in.jpg